Suppression of RPN2 was observed to be able to inhibit malignant breast tumors by inhibiting glycosylation of CD63 [23], which is a glycoprotein at the cell surface controlling cell mobility and invasiveness, as well as metastasis [24]. Here, RPN2 is linked to breast cancer.